TY - JOUR
T1 - Outcomes of Rehepatectomy for Colorectal Liver Metastases
T2 - A Contemporary Multi-Institutional Analysis from the French Surgical Association Database
AU - On behalf of French Colorectal Liver Metastases Working Group. Association Française de Chirurgie (AFC)
AU - Hallet, Julie
AU - Cunha, Antonio Sa
AU - Adam, Rene
AU - Goéré, Diane
AU - Azoulay, Daniel
AU - Mabrut, Jean Yves
AU - Muscari, Fabrice
AU - Laurent, Christophe
AU - Navarro, Francis
AU - Pessaux, Patrick
AU - Cosse, Cyril
AU - Lignier, Delphine
AU - Regimbeau, Jean Marc
AU - Barbieux, Julien
AU - Lermite, Emilie
AU - Hamy, Antoine
AU - Mauvais, François
AU - Al Naasan, Irchid
AU - Laurent, Alexis
AU - Compagnon, Philippe
AU - Lim, Chetana
AU - Mohammed, Sbai Idrissi
AU - Martin, Fréderic
AU - Atger, Jerôme
AU - Baulieux, Jacques
AU - Darnis, Benjamin
AU - Kepenekian, Vahan
AU - Perinel, Julie
AU - Adham, Mustapha
AU - Glehen, Olivier
AU - Rivoire, Michel
AU - Hardwigsen, Jean
AU - Palen, Anais
AU - Grégoire, Emilie
AU - LeTreut, Y. P.
AU - Delpero, Jean Robert
AU - Turrini, Olivier
AU - Herrero, Astrid
AU - Panaro, Fabrizio
AU - Ayav, Ahmet
AU - Bresler, Laurent
AU - Rauch, Philippe
AU - Guillemin, François
AU - Marchal, Fréderic
AU - Gugenheim, Jean
AU - Iannelli, Antonio
AU - Bicêtre, Kremlin
AU - Benoist, Stephane
AU - Brouquet, Antoine
AU - Gelli, Maximiliano
N1 - Publisher Copyright:
© 2016, Society of Surgical Oncology.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background: Recurrence remains frequent after curative-intent hepatectomy for colorectal liver metastases (CRLM). We sought to define short- and long-term outcomes, and identify prehepatectomy factors associated with survival, following rehepatectomy (RH) for recurrence. Methods: We conducted a multi-institutional cohort study of hepatectomy for CRLM over 2006–2013. Second-stage resections were excluded. Primary outcomes were overall survival (OS) and recurrence-free survival (RFS) assessed using Kaplan–Meier methods. Secondary outcomes included 30-day overall morbidity and mortality, and survival from recurrence. Outcomes of RH and initial hepatectomy (IH) were compared. Results: Of 2771 hepatectomies included in the study, 447 were RH. Median operative time, 30-day morbidity, mortality, and median length of stay did not differ for RH and IH. Five-year OS did not statistically differ, i.e. 56.5 % from RH and 67.6 % from IH [adjusted hazard ratio (HR) 0.9, 95 % confidence interval (CI) 0.5–1.7], and 5-year RFS was inferior after RH (18.5 vs. 28.8 %; adjusted HR 1.3, 95 % CI 1.0–1.7). In patients who eventually recurred, 5-year survival from the time of recurrence did not differ whether it was after RH (46.5 %) or after IH (60.3 %) (adjusted HR 1.1, 95 % CI 0.8–1.8). Rectal primary tumor (HR 1.4, 95 % CI 1.0–2.1) and metastasis ≥3 cm (HR 1.3, 95 % CI 1.1–2.7) were independently associated with RFS, but not OS, after RH. Conclusion: Short-term outcomes of RH did not differ from IH. While recurrence was more frequent after RH than IH, it did not impact OS. Survival from the time of recurrence did not differ whether recurrence occurred after RH or after IH. CRLM recurrence can be treated with curative intent with excellent long-term outcomes.
AB - Background: Recurrence remains frequent after curative-intent hepatectomy for colorectal liver metastases (CRLM). We sought to define short- and long-term outcomes, and identify prehepatectomy factors associated with survival, following rehepatectomy (RH) for recurrence. Methods: We conducted a multi-institutional cohort study of hepatectomy for CRLM over 2006–2013. Second-stage resections were excluded. Primary outcomes were overall survival (OS) and recurrence-free survival (RFS) assessed using Kaplan–Meier methods. Secondary outcomes included 30-day overall morbidity and mortality, and survival from recurrence. Outcomes of RH and initial hepatectomy (IH) were compared. Results: Of 2771 hepatectomies included in the study, 447 were RH. Median operative time, 30-day morbidity, mortality, and median length of stay did not differ for RH and IH. Five-year OS did not statistically differ, i.e. 56.5 % from RH and 67.6 % from IH [adjusted hazard ratio (HR) 0.9, 95 % confidence interval (CI) 0.5–1.7], and 5-year RFS was inferior after RH (18.5 vs. 28.8 %; adjusted HR 1.3, 95 % CI 1.0–1.7). In patients who eventually recurred, 5-year survival from the time of recurrence did not differ whether it was after RH (46.5 %) or after IH (60.3 %) (adjusted HR 1.1, 95 % CI 0.8–1.8). Rectal primary tumor (HR 1.4, 95 % CI 1.0–2.1) and metastasis ≥3 cm (HR 1.3, 95 % CI 1.1–2.7) were independently associated with RFS, but not OS, after RH. Conclusion: Short-term outcomes of RH did not differ from IH. While recurrence was more frequent after RH than IH, it did not impact OS. Survival from the time of recurrence did not differ whether recurrence occurred after RH or after IH. CRLM recurrence can be treated with curative intent with excellent long-term outcomes.
UR - http://www.scopus.com/inward/record.url?scp=84984653574&partnerID=8YFLogxK
U2 - 10.1245/s10434-016-5506-7
DO - 10.1245/s10434-016-5506-7
M3 - Article
C2 - 27573524
AN - SCOPUS:84984653574
SN - 1068-9265
VL - 23
SP - 894
EP - 903
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
ER -